Compare PIPR & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PIPR | ERAS |
|---|---|---|
| Founded | 1895 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 6.3B |
| IPO Year | 2003 | 2021 |
| Metric | PIPR | ERAS |
|---|---|---|
| Price | $60.99 | $13.98 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $74.75 | $25.10 |
| AVG Volume (30 Days) | 671.9K | ★ 5.1M |
| Earning Date | 10-30-2026 | 11-12-2026 |
| Dividend Yield | ★ 1.27% | N/A |
| EPS Growth | N/A | ★ 36.23 |
| EPS | ★ 2.65 | N/A |
| Revenue | ★ $1,904,217,000.00 | N/A |
| Revenue This Year | $4.26 | N/A |
| Revenue Next Year | $12.20 | N/A |
| P/E Ratio | $23.68 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $61.35 | $2.81 |
| 52 Week High | $309.45 | $24.28 |
| Indicator | PIPR | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 35.47 | 44.12 |
| Support Level | N/A | $13.18 |
| Resistance Level | $78.49 | $15.71 |
| Average True Range (ATR) | 2.17 | 1.31 |
| MACD | -0.45 | -0.12 |
| Stochastic Oscillator | 0.28 | 19.91 |
Piper Sandler Cos is an investment bank and institutional securities firm, serving the needs of corporations, private equity groups, public entities, non-profit entities, and institutional investors in the United States (U.S.) and internationally. The company provides a broad set of products and services, including financial advisory services; equity and debt capital markets products; public finance services; institutional brokerage services; fundamental equity and macro research services; fixed income services; and alternative asset management strategies. It generates maximum revenue from Advisory services.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.